Lorlatinib
Lorlatinib is a pharmaceutical drug with 48 clinical trials. Currently 17 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
9
Early Stage
16
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
63.2%
12 of 19 finished
36.8%
7 ended early
17
trials recruiting
48
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Clinical Trials (48)
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
Lorlatinib Continuation Study
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 48